Altitudinal variation in growth, photosynthetic capacity and water use efficiency of Abies faxoniana Rehd. et Wils. seedlings as revealed by reciprocal transplantations

Altitudinal variation in morphological, physiological and biochemical characteristics between two provenances of Abies faxoniana Rehd. et Wils. from contrasting elevations (3,500 and 2,850 m) was investigated by reciprocal transplantations in the eastern Qinghai-Tibetan Plateau. From each altitude, 54 seedlings were selected, of which 27 seedlings were simply transplanted at their original altitude, while the other 27 seedlings were reciprocally transplanted to another altitude. The results showed that there is evident altitudinal variation in growth, photosynthetic capacity and water use efficiency among A. faxoniana seedlings. Transplantation of seedlings to a lower altitude decreased the leaf pigment content, leaf N content and water use efficiency, but increased CE, P _n, LMR and PNUE, consequently promoting NAR, the biomass accumulation and branchlet length increment. Besides, the increase in the C/N ratio reduced the risk of pathogen attack. Based on the substantial plasticity in the responses of the seedlings, we infer that the ongoing climate warming might facilitate the growth of A. faxoniana seedlings at high altitudes.     

An Integrated Approach to Uncover Driver Genes in Breast Cancer Methylation Genomes

Background

Cancer cells typically exhibit large-scale aberrant methylation of gene promoters. Some of the genes with promoter methylation alterations play “driver” roles in tumorigenesis, whereas others are only “passengers”.

Results

Based on the assumption that promoter methylation alteration of a driver gene may lead to expression alternation of a set of genes associated with cancer pathways, we developed a computational framework for integrating promoter methylation and gene expression data to identify driver methylation aberrations of cancer. Applying this approach to breast cancer data, we identified many novel cancer driver genes and found that some of the identified driver genes were subtype-specific for basal-like, luminal-A and HER2+ subtypes of breast cancer.

Conclusion

The proposed framework proved effective in identifying cancer driver genes from genome-wide gene methylation and expression data of cancer. These results may provide new molecular targets for potential targeted and selective epigenetic therapy.     

Differential Regulation of TLR Signaling on the Induction of Antiviral Interferons in Human Intestinal Epithelial Cells Infected with Enterovirus 71

Enterovirus 71 (EV71) causes hand-foot-and-mouth disease, which can lead to fatal neurological complications in young children and infants. Few gastrointestinal symptoms are observed clinically, suggesting the presence of a unique immunity to EV71 in the gut. We reported a robust induction of interferons (IFNs) in human intestinal epithelial cells (HT-29), which was suppressed in other types such as RD and HeLa cells. The underlying mechanism for the apparent difference remains obscure. In this study we report that in EV71-infected HT-29 cells, TLR/TRIF signaling was essential to IFN induction; viral replication increased and the induction of IFN-α, -β, -ω, -κ, and -ε decreased markedly in TRIF-silenced HT-29 cells. Importantly, TRIF was degraded by viral 3C^pro in RD cells, but resisted cleavage, and IRF3 was activated and translocated into the nucleus in HT-29 cells. Taken together, our data suggest that IFNs were induced differentially in human HT-29 cells through an intact TLR/TRIF signaling, which differs from other cell types and may be implicated in viral pathogenesis in EV71 infection.     

Traction force-mediated B cell activation: how and why

<正>B and T lymphocytes are responsible for the acquisition of adaptive immune response, among which, B cells dominate humoral immunity. In vivo, B cells utilize surface expressed B cell receptors (BCRs) to sense antigens presented by antigen-presenting cells (APCs), and eventually mediate antibody response and immune memory. It is well recognized     

An Efficient Separator with Low Li‐Ion Diffusion Energy Barrier Resolving Feeble Conductivity for Practical Lithium–Sulfur Batteries

Due to unprecedented features including high‐energy density, low cost, and light weight, lithium–sulfur batteries have been proposed as a promising successor of lithium‐ion batteries. However, unresolved detrimental low Li‐ion transport rates in traditional carbon materials lead to large energy barrier in high sulfur loading batteries, which prevents the lithium–sulfur batteries from commercialization. In this report, to overcome the challenge of increasing both the cycling stability and areal capacity, a metallic oxide composite (NiCo₂O₄@rGO) is designed to enable a robust separator with low energy barrier for Li‐ion diffusion and simultaneously provide abundant active sites for the catalytic conversion of the polar polysulfides. With a high sulfur‐loading of 6 mg cm^?2 and low sulfur/electrolyte ratio of 10, the assembled batteries deliver an initial capacity of 5.04 mAh cm^?2 as well as capacity retention of 92% after 400 cycles. The metallic oxide composite NiCo₂O₄@rGO/PP separator with low Li‐ion diffusion energy barrier opens up the opportunity for lithium–sulfur batteries to achieve long‐cycle, cost‐effective operation toward wide applications in electric vehicles and electronic devices.     

Carbon Quantum Dots–Modified Interfacial Interactions and Ion Conductivity for Enhanced High Current Density Performance in Lithium–Sulfur Batteries

Significant progress has achieved for developing lithium–sulfur (Li–S) batteries with high specific capacities and excellent cyclic stability. However, some critical issues emerge when attempts are made to raise the areal sulfur loading and increase the operation current density to meet the standards for various industrial applications. In this work, polyethylenimine‐functionalized carbon dots (PEI‐CDots) are designed and prepared for enhancing performance of the Li–S batteries with high sulfur loadings and operation under high current density situations. Strong chemical binding effects towards polysulfides and fast ion transport property are achieved in the PEI‐CDots‐modified cathodes. At a high current density of 8 mA cm^?2, the PEI‐CDots‐modified Li–S battery delivers a reversible areal capacity of 3.3 mAh cm^?2 with only 0.07% capacity decay per cycle over 400 cycles at 6.6 mg sulfur loading. Detailed analysis, involving electrochemical impedance spectroscopy, cyclic voltammetry, and density functional theory calculations, is done for the elucidation of the underlying enhancement mechanism by the PEI‐CDots. The strongly localized sulfur species and the promoted Li⁺ ion conductivity at the cathode–electrolyte interface are revealed to enable high‐performance Li–S batteries with high sulfur loading and large operational current.     

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy

Cancer immunotherapy is a new therapeutic strategy for cancer treatment that targets tumors by improving or restoring immune system function. Therapies targeting immune checkpoint molecules have exerted potent anti-tumor effects and prolonged the overall survival rate of patients. However, only a small number of patients benefit from the treatment. Oncolytic viruses exert anti-tumor effects by regulating the tumor microenvironment and affecting multiple steps of tumor immune circulation. In this study, we engineered two oncolytic viruses that express mouse anti-PD-1 antibody (VT1093M) or mouse IL-12 (VT1092M). We found that both oncolytic viruses showed significant anti-tumor effects in a murine CT26 colon adenocarcinoma model. Importantly, the intratumoral combined injection with VT1092M and VT1093M inhibited growth of the primary tumor, prevented growth of the contralateral untreated tumor, produced a vaccine-like response, activated antigen-specific T cell responses and prolonged the overall survival rate of mice. These results indicate that combination therapy with the engineered oncolytic virus may represent a potent immunotherapy strategy for cancer patients, especially those resistant to PD-1/PD-L1 blockade therapy.